Market Size of Enzyme Inhibitors Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.95 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Enzyme Inhibitors Market Analysis
The enzyme inhibitors market is projected to register a CAGR of 3.95% during the forecast period.
- The COVID-19 pandemic had a significant impact on the enzyme inhibitors market. With the emergence of the infectious and virulent coronavirus in the past year, it became essential to understand the cause of the infection. Enzyme inhibitors have helped investigate the enzymes responsible for allowing viral entry and the potential for inhibition to reduce the severity or prevent COVID-19.
- For instance, a study published by Elsevier Public Health Emergency Collection in October 2021 identified enzymes responsible for SARS-CoV-2 viral entry into cells and compounds proposed to inhibit viral access to treat COVID-19 infection. Thus, the increasing number of COVID-19 cases led to a growing demand for enzyme inhibitors. However, due to the increased vaccination and availability of other drugs for COVID-19 treatment, the market has lost some traction gained during the pandemic. Nevertheless, the market is expected to have favorable growth due to the presence of other infections over the forecast period.
- The growth of the enzyme inhibitors market can also be attributed to the increasing demand for effective and accurate drugs, the exponential rise in diseases like cancer, and rising global agricultural activities and pharmaceutical establishments. For example, cancer is a complex multifactorial disease that results from alterations in many physiological and biochemical functions. Cancer cells can acquire multidrug resistance to conventional anticancer drugs, resulting in tumor relapse. Thus, there is a continuous need to discover new and effective anticancer drugs, which is expected to increase the demand for enzyme inhibitors and drive the market's growth. The rising trend of launches, acquisitions, and collaborations in the pharmaceutical industry also drives the market's growth.
- The Cancer Facts & Figures 2023 data published by the American Cancer Society shows an estimated 1.9 million new cancer cases diagnosed and 609,820 cancer deaths in the US in 2023. The exponential rise in the prevalence of diseases like cancer is expected to drive the market's growth. In April 2021, Artios Pharma Limited collaborated with Novartis International AG to uncover and verify new generation DDR targets to advance Novartis' Radioligand Therapies. Additionally, in March 2021, Amgen Inc acquired Rodeo Therapeutics Corporation, recognizing the potential value and differentiated profile of Rodeo's lead 15-prostaglandin dehydrogenase inhibitor program.
- However, the patent expirations of enzyme inhibitor drugs and the availability of low-cost generic drugs restrain the market growth. Overall, the enzyme inhibitors market is expected to grow over the forecast period, driven by the factors mentioned above.
Enzyme Inhibitors Industry Segmentation
As per the scope of this report, enzyme inhibitors are a molecule that binds to an enzyme reversibly or irreversibly and decreases or completely inhibits its catalytic activity. Enzyme inhibitors are naturally occurring and made up of protein.
The enzyme inhibitors market is segmented by type (proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, and other types), application (medical, agriculture, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Type | |
| Proton Pump Inhibitors [PPIs] | |
| Protease Inhibitors | |
| Reverse Transcriptase Inhibitors | |
| Kinase Inhibitors | |
| Other Types |
| By Application | |
| Medical | |
| Agriculture | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Enzyme Inhibitors Market Size Summary
The enzyme inhibitors market is poised for growth, driven by the increasing demand for effective pharmaceuticals and the rising prevalence of diseases such as cancer. The market's expansion is supported by the ongoing need for innovative anticancer drugs, as traditional treatments often lead to drug resistance. This demand is further bolstered by the pharmaceutical industry's trend of mergers, acquisitions, and collaborations, which are aimed at enhancing drug development and market reach. The COVID-19 pandemic initially spurred interest in enzyme inhibitors due to their potential role in understanding and combating viral infections, although the market has since stabilized as other treatments became more widely available. Despite challenges such as patent expirations and the availability of generic alternatives, the market is expected to continue its upward trajectory over the forecast period.
In North America, the enzyme inhibitors market is experiencing robust growth, attributed to a well-established healthcare infrastructure and supportive government policies. The region's high incidence of cancer significantly contributes to market expansion, as innovative enzyme inhibitor products are developed to address various health conditions. The introduction of new therapies, such as those targeting age-related macular degeneration and COVID-19, underscores the dynamic nature of the market. The competitive landscape is moderately concentrated, with major players like Abbott Laboratories, Amgen Inc., and AstraZeneca PLC holding significant market shares. Strategic acquisitions and product launches, such as AstraZeneca's acquisition of CinCor Pharma, are expected to further drive market growth by enhancing the therapeutic offerings available to patients.
Enzyme Inhibitors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Demand for Effective and Accurate Drugs
-
1.2.2 Exponential Rise in the Incidence of Diseases like Cancer
-
1.2.3 Rising Global Agricultural Activities and Pharmaceutical Establishments
-
-
1.3 Market Restraints
-
1.3.1 Patent Expirations of Enzyme Inhibitor Drugs
-
1.3.2 Low-cost Generic Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Type
-
2.1.1 Proton Pump Inhibitors [PPIs]
-
2.1.2 Protease Inhibitors
-
2.1.3 Reverse Transcriptase Inhibitors
-
2.1.4 Kinase Inhibitors
-
2.1.5 Other Types
-
-
2.2 By Application
-
2.2.1 Medical
-
2.2.2 Agriculture
-
2.2.3 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 United Kingdom
-
2.3.2.2 France
-
2.3.2.3 Germany
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 India
-
2.3.3.2 China
-
2.3.3.3 Japan
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Enzyme Inhibitors Market Size FAQs
What is the current Enzyme Inhibitors Market size?
The Enzyme Inhibitors Market is projected to register a CAGR of 3.95% during the forecast period (2024-2029)
Who are the key players in Enzyme Inhibitors Market?
Abbott Laboratories, AstraZeneca PLC, Bayer Ag, Boehringer Ingelheim International GmbH and Amgen Inc. are the major companies operating in the Enzyme Inhibitors Market.
